From: Impact of HIV viral diversity and baseline resistance on treatment outcomes and the emergence of resistance: the CASTLE study 48-week results
ATV/r n/N (%)
LPV/r n/N (%)
Overall*
343/440 (78)
338/443 (76)
Subtype B
230/291 (79)
210/283 (74)
Subtype Non-B
107/143 (75)
121/148 (82)
AE
23/28 (82)
25/28 (89)
BF
21/27 (78)
31/38 (82)
C
51/73 (70)
52/65 (80)
Other
12/15 (80)
13/17 (76)